<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164564</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 084</org_study_id>
    <secondary_id>38070</secondary_id>
    <nct_id>NCT03164564</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women</brief_title>
  <official_title>A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of the long-acting injectable agent&#xD;
      cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine&#xD;
      (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the long-acting&#xD;
      injectable integrase inhibitor cabotegravir (CAB LA) compared to daily oral tenofovir&#xD;
      disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in a&#xD;
      population of sexually active HIV-uninfected women at risk for HIV.&#xD;
&#xD;
      This study will take place in three steps. Participants will be randomly assigned to one of&#xD;
      two arms:&#xD;
&#xD;
      Arm A:&#xD;
&#xD;
      Step 1: Participants will receive daily oral CAB and TDF/FTC placebo for 5 weeks.&#xD;
&#xD;
      Step 2: Participants will receive injections of CAB LA at two time points 4 weeks apart and&#xD;
      every 8 weeks thereafter and daily TDF/FTC placebo beginning at Week 5.&#xD;
&#xD;
      Arm B:&#xD;
&#xD;
      Step 1: Participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks.&#xD;
&#xD;
      Step 2: Participants will receive daily TDF/FTC and intramuscular (IM) placebo injections at&#xD;
      two time points 4 weeks apart and every 8 weeks thereafter beginning at Week 5.&#xD;
&#xD;
      Step 2 will continue until the last enrolled participant reaches approximately 76 weeks on&#xD;
      Step 2 (Week 81 for the last enrolled participant).&#xD;
&#xD;
      In Step 3, all participants (Arms A and B) will receive daily TDF/FTC for up to 48 weeks,&#xD;
      starting no later than 8 weeks after the last injection.&#xD;
&#xD;
      At the end of Step 3, all participants will then transition to locally available HIV&#xD;
      prevention services, including services for PrEP, if available.&#xD;
&#xD;
      Study visits will occur at Day 0 and at Weeks 2 and 4 during Step 1. During Step 2,&#xD;
      participants will attend up to 24 visits, depending on when they enroll in the study. Study&#xD;
      visits will occur every 12 weeks during Step 3. Study visits may include physical&#xD;
      examinations; blood, urine, and vaginal swab collection; risk reduction, adherence&#xD;
      counseling, and contraception counseling.&#xD;
&#xD;
      HPTN 084-01 is a sub-study of HPTN 084. The purpose of this study is to examine the safety,&#xD;
      tolerability, and acceptability of CAB LA for the prevention of HIV among adolescent females.&#xD;
      Participants will receive oral CAB for 5 weeks, followed by 34 weeks on CAB LA, then&#xD;
      quarterly visits for 48 weeks after final injection. All participants who have received at&#xD;
      least one injection will be followed for 48 weeks after their last injection. Total study&#xD;
      duration per participant will be approximately 21 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of documented incident HIV infections in Steps 1 and 2</measure>
    <time_frame>Measured through Week 81</time_frame>
    <description>HIV incidence rate will be calculated as the total number of participants with confirmed incident HIV infection during study follow-up of Step 1 and Step 2 divided by the person-years accumulated in each arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Grade 2 or higher clinical and laboratory adverse events (AEs)</measure>
    <time_frame>Measured through participant's last study visit, up to 4.6 years after study entry, depending on when they enroll in the study</time_frame>
    <description>AEs will be summarized using MedDRA System Organ Class and preferred terms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of documented incident HIV infections in Steps 1, 2 and 3</measure>
    <time_frame>Measured through participant's last study visit, up to 4.6 years after study entry, depending on when they enroll in the study</time_frame>
    <description>For each of the specified baseline factors, a Cox proportional hazards model will be fit with treatment arm, baseline factor and their interaction as covariates, stratified by site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of documented incident HIV infections in participants in subgroups broken down by baseline age</measure>
    <time_frame>Measured through participant's last study visit, up to 4.6 years after study entry, depending on when they enroll in the study</time_frame>
    <description>For each of the specified baseline factors, a Cox proportional hazards model will be fit with treatment arm, baseline factor and their interaction as covariates, stratified by site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of documented incident HIV infections in participants in subgroups broken down by baseline HSV-2 status</measure>
    <time_frame>Measured through participant's last study visit, up to 4.6 years after study entry, depending on when they enroll in the study</time_frame>
    <description>For each of the specified baseline factors, a Cox proportional hazards model will be fit with treatment arm, baseline factor and their interaction as covariates, stratified by site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of documented incident HIV infections in participants in subgroups broken down by baseline contraceptive use method</measure>
    <time_frame>Measured through participant's last study visit, up to 4.6 years after study entry, depending on when they enroll in the study</time_frame>
    <description>For each of the specified baseline factors, a Cox proportional hazards model will be fit with treatment arm, baseline factor and their interaction as covariates, stratified by site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of documented incident HIV infections in participants in subgroups broken down by baseline body mass index (BMI) less than/greater than or equal to 25 kg/m^2</measure>
    <time_frame>Measured through participant's last study visit, up to 4.6 years after study entry, depending on when they enroll in the study</time_frame>
    <description>For each of the specified baseline factors, a Cox proportional hazards model will be fit with treatment arm, baseline factor and their interaction as covariates, stratified by site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of CAB in participants randomized to CAB/CAB LA</measure>
    <time_frame>Measured through participant's last study visit, up to 4.6 years after study entry, depending on when they enroll in the study</time_frame>
    <description>Plasma samples for drug concentrations will be collected throughout the study from all participants, although PK testing may be limited to a subset of the samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and dried blood spot (DBS) concentrations of tenofovir/tenofovir diphosphate (TFV/TFV-DP) in a subset of participants randomized to TDF/FTC</measure>
    <time_frame>Measured through participant's last study visit, up to 4.6 years after study entry, depending on when they enroll in the study</time_frame>
    <description>Plasma and DBS samples for drug concentrations will be collected throughout the study from all participants, although PK testing may be limited to a subset of the samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants willing to use CAB LA and TDF/FTC</measure>
    <time_frame>Measured through participant's last study visit, up to 4.6 years after study entry, depending on when they enroll in the study</time_frame>
    <description>Assessed through administration of brief behavioral surveys.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Arm A: CAB + Placebo TDF/FTC + CAB LA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Step 1, participants will receive daily oral CAB and oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily oral TDF/FTC placebo beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During Step 1, participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. In Step 2, participants will receive daily TDF/FTC and placebo for CAB LA injections at two times points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral CAB</intervention_name>
    <description>CAB 30 mg tablet</description>
    <arm_group_label>Arm A: CAB + Placebo TDF/FTC + CAB LA</arm_group_label>
    <other_name>Cabotegravir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral TDF/FTC</intervention_name>
    <description>TDF/FTC 300 mg/200 mg fixed dose combination tablet</description>
    <arm_group_label>Arm A: CAB + Placebo TDF/FTC + CAB LA</arm_group_label>
    <arm_group_label>Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA</arm_group_label>
    <other_name>Tenofovir disoproxil fumarate/emtricitabine</other_name>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for oral CAB</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for oral TDF/FTC</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>Arm A: CAB + Placebo TDF/FTC + CAB LA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAB LA</intervention_name>
    <description>600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle</description>
    <arm_group_label>Arm A: CAB + Placebo TDF/FTC + CAB LA</arm_group_label>
    <other_name>Cabotegravir long-acting injectable</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for CAB LA</intervention_name>
    <description>Administered as one 3 mL intramuscular injection in the gluteal muscle</description>
    <arm_group_label>Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Born female&#xD;
&#xD;
          -  18-45 years at the time of screening&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Willing and able to undergo all required study procedures&#xD;
&#xD;
          -  Non-reactive HIV test results at Screening and Enrollment. Note: HIV-uninfected, based&#xD;
             on HIV test results obtained at Screening and just prior to randomization at the&#xD;
             Enrollment visit. All HIV test results from the Screening visit must be obtained and&#xD;
             must all be negative/non-reactive. This includes testing for acute HIV infection,&#xD;
             which must be performed within 14 days of Enrollment. In addition, at least one HIV&#xD;
             test result using blood drawn at the Enrollment visit must be obtained prior to&#xD;
             randomization into the study and must be negative/non-reactive. Individuals who have&#xD;
             one or more reactive or positive HIV test result(s) will not be enrolled, even if&#xD;
             subsequent confirmatory testing indicates that they are not HIV-infected (see SSP&#xD;
             Manual). Those with any enrollment HIV test result positive will proceed through the&#xD;
             HIV algorithm per the SSP but will not be able to receive study product regardless of&#xD;
             subsequent test results.&#xD;
&#xD;
          -  Sexually active (i.e., vaginal intercourse on a minimum of two separate days in the 30&#xD;
             days prior to Screening)&#xD;
&#xD;
          -  Score of greater than or equal to 5 using a modified VOICE risk score&#xD;
&#xD;
          -  No plans to re-locate or travel away from the site for greater than or equal to 8&#xD;
             consecutive weeks during study participation&#xD;
&#xD;
          -  Creatinine clearance of greater than or equal to 60 mL/min (using Cockcroft-Gault&#xD;
             equation) (use sex at birth for calculation)&#xD;
&#xD;
               -  Although not protocol exclusionary, sites should carefully consider the&#xD;
                  advisability of enrolling participants with calculated creatinine clearance&#xD;
                  between 60-70 mL/min, as limited changes in creatinine clearance during study&#xD;
                  conduct will lead to protocol-mandated product holds and may alter the&#xD;
                  risk-benefit considerations of study participation&#xD;
&#xD;
          -  Hepatitis B virus (HBV) surface antigen (HBsAg) negative and accepts vaccination&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) less than 2 x upper limit of normal (ULN) and total&#xD;
             bilirubin (Tbili) less than or equal to 2.5 x ULN&#xD;
&#xD;
          -  HCV antibody negative&#xD;
&#xD;
          -  If of reproductive potential (defined as pre-menopausal women who have not had a&#xD;
             sterilization procedure per self-report, such as hysterectomy, bilateral oophorectomy,&#xD;
             tubal ligation or salpingectomy), must have a negative beta human chorionic&#xD;
             gonadotropin (Î²HCG) pregnancy test (sensitivity of less than or equal to 25 mIU/mL)&#xD;
             performed (and results known) on the same day as and before initiating the&#xD;
             protocol-specified study product(s) at Enrollment.&#xD;
&#xD;
          -  Have documented evidence of surgical sterilization, OR documented evidence of no&#xD;
             uterus (e.g., hysterectomy), OR must agree to use a reliable form of long acting&#xD;
             contraception, during the trial and for 52 weeks after stopping the long acting&#xD;
             injectable, or 30 days after stopping oral study product, from the list below:&#xD;
&#xD;
               -  Intrauterine device (IUD) or intrauterine system (IUS) that meets less than 1%&#xD;
                  failure rate as stated in the product label&#xD;
&#xD;
               -  Hormone-based contraceptive that meets less than 1% failure rate when used&#xD;
                  consistently and correctly as stated in the product label (implants or&#xD;
                  injectables only; this excludes combined oral contraception)&#xD;
&#xD;
          -  No medical condition that, in the opinion of the study investigator, would interfere&#xD;
             with the conduct of the study (e.g., provided by self-report, or found upon medical&#xD;
             history and examination or in available medical records)&#xD;
&#xD;
          -  No alcohol or substance use that, in the opinion of the study investigator, would&#xD;
             interfere with the conduct of the study (e.g., provided by self-report, or found upon&#xD;
             medical history and examination or in available medical records)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  One or more reactive HIV test results at Screening or Enrollment, even if HIV&#xD;
             infection is not confirmed&#xD;
&#xD;
          -  Pregnant or currently breastfeeding, or intends to become pregnant and/or breastfeed&#xD;
             during the study&#xD;
&#xD;
          -  Co-enrollment in any other HIV interventional research study (provided by self-report&#xD;
             or other available documentation), with one exception: IMPAACT 2026 (co-enrollment in&#xD;
             IMPAACT 2026 is permitted for participants who become pregnant)&#xD;
&#xD;
          -  Current or past enrollment in an HIV vaccine or broadly neutralizing antibody trial&#xD;
&#xD;
          -  Current or chronic history of liver disease (e.g., non-alcoholic or alcoholic&#xD;
             steatohepatitis) or known hepatic or biliary abnormalities (with the exception of&#xD;
             Gilbert's syndrome, asymptomatic gallstones, or cholecystectomy)&#xD;
&#xD;
          -  History of seizure disorder, per self-report&#xD;
&#xD;
          -  Clinically significant cardiovascular disease, as defined by history/evidence of&#xD;
             symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG)&#xD;
             surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically&#xD;
             significant cardiac disease&#xD;
&#xD;
          -  Inflammatory skin conditions that compromise the safety of IM injections, per the&#xD;
             discretion of the Investigator of Record (IoR). Mild skin conditions may not be&#xD;
             exclusionary at the discretion of the IoR or designee&#xD;
&#xD;
          -  Has a tattoo or other dermatological condition overlying the buttock region which in&#xD;
             the opinion of the IoR or designee may interfere with interpretation of injection site&#xD;
             reactions (ISRs)&#xD;
&#xD;
          -  Coagulopathy (primary or iatrogenic) which would contraindicate IM injection&#xD;
&#xD;
          -  Active or planned use of prohibited medications as described in the Investigator&#xD;
             Brochure (IB) or listed in the Study Specific Procedures Manual (SSP) (provided by&#xD;
             self-report, or obtained from medical history or medical records)&#xD;
&#xD;
          -  Known or suspected allergy to study product components (active or placebo), including&#xD;
             egg or soy products (egg and soy products are contained in Intralipid)&#xD;
&#xD;
          -  If potentially able to conceive, unwilling to adhere to long acting contraception&#xD;
             (IUD/IUS, injection, or implant) with a less than 1% failure rate when used&#xD;
             consistently and correctly as stated in the product package insert/ manufacturer's&#xD;
             guidelines&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sinead Delany-Moretlwe, MBBCh, PhD, DTM&amp;H</last_name>
    <role>Study Chair</role>
    <affiliation>Wits Reproductive Health and HIV Institute CRS (WRHI CRS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mina Hosseinipour, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of North Carolina (UNC) Project-Malawi, Tidziwe Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gaborone CRS</name>
      <address>
        <city>Gaborone</city>
        <state>South-East District</state>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kisumu Crs</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malawi CRS</name>
      <address>
        <city>Lilongwe</city>
        <state>Central</state>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blantyre CRS</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto HPTN CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ward 21 CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Botha's Hill CRS</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <zip>3660</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isipingo CRS</name>
      <address>
        <city>Isipingo</city>
        <state>Kwa Zulu Natal</state>
        <zip>4110</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Verulam CRS</name>
      <address>
        <city>Verulam</city>
        <state>Kwa Zulu Natal</state>
        <zip>4340</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape Province</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emavundleni CRS</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7750</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eswatini Prevention Center CRS</name>
      <address>
        <city>Mbabane</city>
        <state>Eswatini</state>
        <country>Swaziland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVRI-IAVI HIV Vaccine Program LTD. CRS</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor-Uganda CRS</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MU-JHU Research Collaboration (MUJHU CARE LTD) CRS</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zengeza CRS</name>
      <address>
        <city>Chitungwiza</city>
        <state>Mashonaland East</state>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seke South CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton Park CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spilhaus CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>South Africa</country>
    <country>Swaziland</country>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Cabotegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

